SIGA RELEASES RESULTS OF SMALLPOX DRUG PHASE I TRIAL

SIGA Technologies announced that its lead smallpox drug candidate, SIGA-246, has successfully completed the first planned human clinical safety trial. Preliminary results indicate that SIGA-246 is safe and well-tolerated in human volunteers at all tested orally administered doses. In addition, data from blood level exposure was sufficient to support once-a-day dosing.

The Phase I clinical trial was performed at Advanced Biomedical Research Clinical Research Center in Hackensack, N.J. The study was a double-blind, randomized, placebo-controlled, ascending single-dose study in healthy volunteers.